Possible Buyers for Geron's Stem Cell Business: BioTime, Pfizer, Celgene
The mainstream media is climbing all over the Geron story today with more analysis and a discussion of firms that might snag the San Francisco area firm's orphan stem cell business.
Reporter Peter Loftus of the Wall Street Journal mentioned Pfizer, which is involved an hESC project with researcher Peter Coffey, who was lured from the UK this fall to UC…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.